Mga Batayang Estadistika
| CIK | 1601830 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Recursion Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 . PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 2,397,023 Shares of Class A Common Stock Offered by the Selling Stockholder We are registering the proposed resale or other disposition from time to time of up to 2,397,023 shares of our Class A Common Stock, par value $0.00001 per share |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 Calculation of Filing Fee Tables S-3 (Form Type) Recursion Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price |
|
| August 5, 2025 |
q22025earningsdeck 2Q25 (L)earnings August 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| August 5, 2025 |
corporatepresentationau Corporate Deck August 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| August 5, 2025 |
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, August 5, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biolog |
|
| July 8, 2025 |
Recursion Acquires Full Rights to REV102, a Potential Exhibit 99.1 Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia SALT LAKE CITY, July 8, 2025 – Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an assoc |
|
| July 8, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 RECURSION PHARMACEUTICALS, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Eff |
|
| July 8, 2025 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 1,457,952 Shares of Class A Common Stock Offered by the Selling Stockholder We are registering the proposed resale or other disposition from time to time of up to 1,457,952 shares of our Class A Common Stock, par value $0.00001 per share ( |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 10, 2025 |
EX-99.1 Exhibit 99.1 Corporate Deck June 2025 Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| May 9, 2025 |
424B7 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to 4,260,927 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 4,260,927 shares of our Class A Common Stock, or th |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-284878 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount registered Proposed maximum offering price per Unit (2) |
|
| May 5, 2025 |
q12025learningsdeck 1Q25 (L)earnings MAY 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| May 5, 2025 |
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Recursion Reports First Quarter 2025 Financial Results and Provides Business Update •Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 pre-clinical program following a strategic, data-driven review •Partnerships: A |
|
| May 5, 2025 |
As filed with the Securities and Exchange Commission on May 5, 2025 As filed with the Securities and Exchange Commission on May 5, 2025 Registration No. |
|
| May 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 18, 2025 |
Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy EXHIBIT 10.1 RECURSION PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Recursion Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Dir |
|
| March 18, 2025 |
EXHIBIT 99.1 Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. SALT LAKE CITY, Mar 18, 2025 (GLOBE NEWSWIRE) - Recursion (N |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| February 28, 2025 |
Exhibit 10.35 EXECUTION VERSION Certain information in this document, marked by brackets [****], has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. RESEARCH COLLABORATION AND LICENCE OPTION AGREEMENT BETWEEN: Sanofi |
|
| February 28, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Recursion Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock, par value $0.00001 per share. As used in this summary, the terms “Recursion,” “the Company |
|
| February 28, 2025 |
Global Access Commitments Agreement between the Registrant and the Bill & Melinda Gates Foundation. Exhibit 4.8 Certain information in this document, marked by brackets [****], has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Global Access Commitments Agreement This Global Access Commitments Agreement (including |
|
| February 28, 2025 |
Transition Agreement between the Registrant and Tina Marriott. Exhibit 10.18 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Tina Marriott (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee is employed at will by the Company; WHEREAS, the Company granted Employee the option(s |
|
| February 28, 2025 |
Recursion Pharmaceuticals, Inc. Up to $500,000,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284878 PROSPECTUS SUPPLEMENT (to Prospectus dated February 12, 2025) Recursion Pharmaceuticals, Inc. Up to $500,000,000 Class A Common Stock We entered into a Sales Agreement, dated February 28, 2025, or the sales agreement, with Citigroup Global Markets Inc., or Citigroup, relating to the sale of shares of our Class A Common Stock, par value $ |
|
| February 28, 2025 |
Exhibit 21.1 List of Subsidiaries The following is a list of subsidiaries of Recursion Pharmaceuticals Inc. as of December 31, 2024. Name of Subsidiary* Jurisdiction of Incorporation Exscientia Limited United Kingdom Exscientia (UK) Holdings Ltd. United Kingdom Exscientia AI Ltd. Scotland Kinetic Discovery Ltd Scotland Exscientia Inc. Delaware Exscientia Ventures I Inc. Delaware RE Ventures I LLC |
|
| February 28, 2025 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-284878 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount registered Proposed maximum offering price per Unit Max |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation or |
|
| February 28, 2025 |
Exhibit 10.39 SALES AGREEMENT February 28, 2025 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Citigroup Global Markets Inc., as sales agent and/or principal (the “Agent”) |
|
| February 28, 2025 |
Exhibit 99.1 Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results •Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous malformations •Advanced three new clinical studies across oncology, rare disease, a |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Phar |
|
| February 28, 2025 |
Recursion Pharmaceuticals, Inc. Insider Trading Policy. Exhibit 19.1 RECURSION PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on March 19, 2021; most recently amended April 27, 2023) A.POLICY OVERVIEW Recursion Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in |
|
| February 28, 2025 |
rxrxlearnings10k2024 Forward-looking statements 2 This presentation of Recursion Pharmaceuticals, Inc. |
|
| February 28, 2025 |
rxrx2025corporatedeck Decoding Biology To Radically Improve Lives FEBRUARY 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| February 28, 2025 |
Confirmatory Employment Letter between the Registrant and Ben Taylor. December 2, 2024 Ben Taylor Confirmatory Employment Letter Dear Ben: Exscientia AI Ltd. |
|
| February 28, 2025 |
EXHIBIT 10.36 EXECUTION VERSION RESEARCH COLLABORATION AGREEMENT dated September 19, 2023 by and between EXSCIENTIA AI LTD. and MERCK HEALTHCARE KGAA Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. RESEARCH COLLABORATION AGREEMENT This Resea |
|
| February 28, 2025 |
Separation Agreement between the Registrant and Michael Secora. Exhibit 10.20 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Michael Secora (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee is employed at will by the Company; WHEREAS, the Company granted Employee the option(s) to pur |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| February 12, 2025 |
As filed with the Securities and Exchange Commission on February 12, 2025 S-3ASR As filed with the Securities and Exchange Commission on February 12, 2025 Registration No. |
|
| February 12, 2025 |
Exhibit 4.9 RECURSION PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establ |
|
| February 12, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Life Limited BlackRock Advisors, LLC Aperio Group, LLC BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited SpiderRock A |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| January 13, 2025 |
Decoding Biology to Radically Improve Lives JANUARY 2025 This presentation of Recursion Pharmaceuticals, Inc. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| December 17, 2024 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| December 17, 2024 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 . PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to 3,498,393 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 3,498,393 shares of our Class A Common Stock, or the Shares, |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 27, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”), as amended by the First Amendment to the Transaction Agreement dated as of November 5, 2024 (the “First Amendment”), with Exscientia plc (“Exscientia”) to acquire the entire issued and to be is |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 RECURSION PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40323 46-4099738 (State or Other Jurisdiction |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 20, 2024 |
Three months ended September 30, Exhibit 99.4 Exscientia plc Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Note £’000 £’000 £’000 £’000 Revenue 4 4,930 8,882 14,639 17,649 Cost of sales (7,530) (6,742) (22,696) (21,468) Gross (loss |
|
| November 20, 2024 |
The Exscientia Unapproved Share Option Plan with RSU Sub-Plan Exhibit 4.4 The Exscientia Unapproved Share Option Plan Plan Rules Adopted by the Board on 13th February 2018 and amended on 25th September 2019 and 1st April 2021 Plan Rules Definitions 1.1 In these Rules (and, where applicable, any Option Agreement) the following words and expressions shall have the following meanings: “Acting in Concert” the meaning given in the City Code on Takeovers and Merge |
|
| November 20, 2024 |
As filed with the Securities and Exchange Commission on November 20, 2024 As filed with the Securities and Exchange Commission on November 20, 2024 Registration No. |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| November 20, 2024 |
exhibit992-closingdeck NOVEMBER 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| November 20, 2024 |
EXHIBIT 99.3 Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery ●Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs ●Platform will focus on first and best-in-class drug di |
|
| November 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| November 20, 2024 |
Exscientia plc 2021 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Sub-Plan Exhibit 4.5 EXSCIENTIA PLC 2021 EQUITY INCENTIVE PLAN WITH NON-EMPLOYEE SUB-PLAN AND CSOP SUB-PLAN ADOPTED BY THE BOARD OF DIRECTORS: 11 AUGUST 2021 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: 23 AUGUST 2021 SHARE RESERVE APPROVED BY THE PRICING COMMITTEE OF THE BOARD OF DIRECTORS: [DATE] 2021 IPO DATE: [DATE] 2021 APPROVED BY THE SHAREHOLDERS: [DATE] 2021 TABLE OF CONTENTS Page 1. PURPOSE 1 2 |
|
| November 20, 2024 |
Plan and forms of agreement thereunder. Exhibit 4.6 RECURSION PHARMACEUTICALS, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nons |
|
| November 13, 2024 |
Recursion and Exscientia Shareholders Approve the Proposed Combination EXHIBIT 99.1 Recursion and Exscientia Shareholders Approve the Proposed Combination ●Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Salt Lake City, Utah, and Oxford, UK, November 13, 2024: Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 (November 12, 2024) RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction |
|
| November 6, 2024 |
Exhibit 2.1 EXECUTION VERSION FIRST AMENDMENT TO TRANSACTION AGREEMENT This first Amendment TO THE TRANSACTION AGREEMENT (this “Amendment”), dated as of November 5, 2024, is by and between Recursion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Exscientia plc, a public limited company incorporated in England and Wales with registered number 13483814 (the “Company”). WHEREAS, Parent |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECUR |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| November 6, 2024 |
November 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 6, 2024 |
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results •Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39), whi |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 6, 2024 (November 5, 2024) Date of Report (date of earliest event reported) RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of |
|
| November 4, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / Kinnevik AB (publ) - SC 13G/A Passive Investment SC 13G/A 1 tm2427110d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 75629V104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| October 18, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 RecursionPharmaInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RECURSION PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75629V104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r |
|
| October 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| October 2, 2024 |
rxrx2024q2corp October 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| October 2, 2024 |
EXHIBIT 99.1 Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma ●First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months ●Plan to initiate dosing of Phase 1/ |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 17, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| September 17, 2024 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 686,475,441. |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 3, 2024 |
exhibit991-rxrxsept2024 September 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| September 3, 2024 |
Exhibit 99.4 Exscientia plc Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Note £’000 £’000 £’000 £’000 Revenue 4 4,419 3,006 9,709 8,767 Cost of sales (7,759) (6,269) (15,166) (14,726) Gross loss (3,340) (3,263) (5,457) (5,9 |
|
| September 3, 2024 |
Exhibit 99.3 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 876) F-2 Consolidated Statement of Loss and Other Comprehensive Loss F-3 Consolidated Statement of Financial Position F-4 Consolidated Statement of Changes in Equity F-6 Consolidated Statement of Cash Flows F-8 Notes to the Financial Statements F-10 F-1 Report of Independ |
|
| September 3, 2024 |
Press Release of Recursion Pharmaceuticals, Inc. dated September 3, 2024. Exhibit 99.2 Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the pote |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| September 3, 2024 |
Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”) with Exscientia plc (“Exscientia”) to acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement (the “Scheme of Arrangement”) under Part 26 of th |
|
| September 3, 2024 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.3 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 876) F-2 Consolidated Statement of Loss and Other Comprehensive Loss F-3 Consolidated Statement of Financial Position F-4 Consolidated Statement of Changes in Equity F-6 Consolidated Statement of Cash Flows F-8 Notes to the Financial Statements F-10 F-1 Report of Independ |
|
| September 3, 2024 |
Exhibit 99.4 Exscientia plc Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Note £’000 £’000 £’000 £’000 Revenue 4 4,419 3,006 9,709 8,767 Cost of sales (7,759) (6,269) (15,166) (14,726) Gross loss (3,340) (3,263) (5,457) (5,9 |
|
| September 3, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 8, 2024, Recursion Pharmaceuticals, Inc. (“Recursion”) entered into a transaction agreement (the “Transaction Agreement”) with Exscientia plc (“Exscientia”) to acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement (the “Scheme of Arrangement”) under Part 26 of th |
|
| September 3, 2024 |
Exhibit 99.2 Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the pote |
|
| September 3, 2024 |
Investor Presentation of Recursion Pharmaceuticals, Inc. dated September 3, 2024. September 2024 Decoding Biology To Radically Improve Lives This presentation of Recursion Pharmaceuticals, Inc. |
|
| August 28, 2024 |
Irrevocable Undertaking of Evotec SE dated August 28, 2024. Exhibit 10.1 INSTITUTIONAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States ("Parent") Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the "Company") August 28, 2024 Dear Sir/Madam Proposed acquisition of the Company 1.ACQUISITION 1.1In this deed of undertaking (the "Unde |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| August 28, 2024 |
Irrevocable Undertaking of Evotec SE dated August 28, 2024. Exhibit 10.1 INSTITUTIONAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States ("Parent") Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the "Company") August 28, 2024 Dear Sir/Madam Proposed acquisition of the Company 1.ACQUISITION 1.1In this deed of undertaking (the "Unde |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 8, 2024 |
EX-2.1 EXHIBIT 2.1 TRANSACTION AGREEMENT by and between EXSCIENTIA PLC and RECURSION PHARMACEUTICALS, INC. Dated as of August 8, 2024 TABLE OF CONTENTS Page ARTICLE I THE TRANSACTION 2 Section 1.01 The Transaction 2 Section 1.02 Closing 2 Section 1.03 Delivery of Court Order 2 ARTICLE II TRANSFER OF SCHEME SHARES; DELIVERY OF EXCHANGE SHARES 3 Section 2.01 Transfer of Scheme Shares 3 Section 2.02 |
|
| August 8, 2024 |
EX-99.1 EXHIBIT 99.1 Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities • Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug |
|
| August 8, 2024 |
EX-99.4 Exhibit 99.4 Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “p |
|
| August 8, 2024 |
Form of Irrevocable Undertaking (Institutional). EX-10.2 EXHIBIT 10.2 INSTITUTIONAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States (“Parent”) Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the “Company”) August 8, 2024 Dear Sir/Madam Proposed acquisition of the Company 1. ACQUISITION 1.1 In this undertaking (the “Und |
|
| August 8, 2024 |
EX-99.3 Exhibit 99.3 Decoding Biology To Radically Improve Lives August 2024 Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as “anticipates,” “b |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2024 |
EX-99.2 EXHIBIT 99.2 Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results • Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities • Recursion expects 7 clinical trial readouts for itself over the next 18 months and approximately 10 c |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2024 |
Form of Irrevocable Undertaking (Individual). EX-10.3 EXHIBIT 10.3 INDIVIDUAL SHAREHOLDER IRREVOCABLE UNDERTAKING To: Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, UT 84101 United States (“Parent”) Exscientia plc The Schrödinger Building Oxford Science Park Oxford OX4 4GE United Kingdom (the “Company”) August 8, 2024 Dear Sir/Madam Proposed acquisition of the Company 1. ACQUISITION 1.1 In this undertaking (the “Undert |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 8, 2024 |
Form of Voting and Support Agreement. EX-10.1 EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (as the same may be amended from time to time in accordance with its terms, this “Agreement”), dated as of August 8, 2024, by and between the undersigned stockholder (the “Stockholder”) in such person’s capacity as a stockholder of Recursion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Exscientia p |
|
| August 8, 2024 |
Employment Offer Letter, dated July 1, 2024, between the Registrant and Dr. Najat Khan, Ph.D. EXHIBIT 10.1 41 S. Rio Grande Street Salt Lake City, Utah 84101 (385) 269-0203 recursionpharma.com July 1, 2024 Najat Khan, Ph.D. Re: Employment Offer Letter Dear Najat: Recursion Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) is truly excited to extend you an offer on the terms and conditions in this letter agreement (the “Agreement”) and hope that you will be joining us in our missi |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| July 8, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 75629V104 (CUSIP Number) June 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| June 27, 2024 |
Exhibit 1.1 Recursion Pharmaceuticals, Inc. 30,769,230 Shares of Class A Common Stock, $0.00001 par value Underwriting Agreement June 26, 2024 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC, As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o J.P. Morgan Securities LLC 383 M |
|
| June 27, 2024 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(5)(1) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount reg |
|
| June 27, 2024 |
30,769,230 Shares Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) 30,769,230 Shares Class A Common Stock We are offering 30,769,230 shares of our Class A common stock, $0.00001 par value per share, or Class A Common Stock, in this offering. Our Class A Common Stock is listed on the Nasdaq Global Select Market under the symbol “RXRX.” On June 26, |
|
| June 27, 2024 |
Recursion Announces Proposed Offering of Class A Common Stock Exhibit 99.1 Recursion Announces Proposed Offering of Class A Common Stock SALT LAKE CITY, Utah – June 26, 2024 – Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offe |
|
| June 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 27, 2024 |
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock Exhibit 99.2 Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock SALT LAKE CITY, UT - June 26, 2024 - Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock |
|
| June 26, 2024 |
Subject to Completion, Dated June 26, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 24, 2024 |
downloadday2024pdf AGENDA PLACEHOLDER Morning Session 9:30 am – 12:30 pm Afternoon Session 1:30 pm – 4:30 pm Welcome State of Recursion Chris Gibson PhD – Co-Founder & CEO Recursion OS Lina Nilsson PhD – Senior VP of Inception Labs Preclinical Laura Schaevitz PhD – Senior VP and Head of Research Fireside Chat with Deepak Nijhawan, MD, PhD David Mauro MD PhD – Chief Medical Officer Deepak Nijhawan |
|
| June 24, 2024 |
Exhibit 99.1 Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Its Download Day ●Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination ●Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discov |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 13, 2024 |
June 13, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Mary Mast Ibolya Ignat Re: Recursion Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 29, 2024 File No. 001-40323 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc. (“Recursion,” “we |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 24, 2024 |
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board Exhibit 99.1 Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur SALT LAKE CITY, US (May 24, 2024) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| May 9, 2024 |
Letter dated May 9, 2024, from Ernst & Young LLP to the Securities Exchange Commission. Exhibit 16.1 May 9, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated May 9, 2024, of Recursion Pharmaceuticals, Inc. and are in agreement with the statements contained in the first, fourth, fifth, sixth and seventh paragraphs and the second sentence of the second paragraph on pages two and three therein. We have |
|
| May 9, 2024 |
Advisory Agreement between the Registrant and Shafique Virani EXHIBIT 10.1 ADVISORY AGREEMENT This Advisory Agreement (this “Agreement”) is made and entered into as of February 6, 2024 (the “Effective Date”) by and between Recursion Pharmaceuticals, Inc., (the “Company”), and Shafique Virani (“Advisor”) (each herein referred to individually as a “Party,” or collectively as the “Parties”). 1.SERVICES AND COMPENSATION Advisor shall perform the services describ |
|
| May 9, 2024 |
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results •On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024 •Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomes •Tra |
|
| May 9, 2024 |
Transition Agreement between the Registrant and Shafique Virani EXHIBIT 10.2 TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (“Agreement”) is made by and between Shafique Virani (“Employee”) and Recursion Pharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed a confirmatory employment lette |
|
| May 9, 2024 |
rxrxlearningsq22024 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2024 |
rxrx2024q1website Decoding Biology To Radically Improve Lives May 2024 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| April 16, 2024 |
Exhibit 99.1 Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors SALT LAKE CITY, April 16th, 2024- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space |
|
| February 29, 2024 |
Recursion Pharmaceuticals, Inc. Compensation Recovery Policy RECURSION PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY As adopted on October 31, 2023 Recursion Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay |
|
| February 29, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Recursion Pharmaceuticals, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock, par value $0.00001 per share. As used in this summary, the terms “Recursion,” “the Company |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Phar |
|
| February 29, 2024 |
Exhibit 21.1 List of Subsidiaries The following is a list of subsidiaries of Recursion Pharmaceuticals Inc. as of December 31, 2023. Name of Subsidiary* Jurisdiction of Incorporation Recursion Pharmaceuticals Canada, Inc. Canada Valence Discovery Inc. Canada Valence Discovery USA, Inc. Delaware Cyclica Therapeutics Inc. Canada Cyclica Ltd. United Kingdom Cyclica Inc. Delaware Giro Health Inc. Dela |
|
| February 29, 2024 |
Exhibit 10.21 CERTAIN INFORMATION, MARKED BY BRACKETS AND ASTERISKS (I.E., [***]), HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amended and Restated Research Collaboration and Option Agreement by and between Bayer AG and Recursion Pharmaceuticals, Inc. TABLE OF CONTENTS Chapter A – Introduc |
|
| February 27, 2024 |
rxrx2023q4learningsfilin Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| February 27, 2024 |
Exhibit 99.1 Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results •Multiple clinical programs from Recursion's first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the near-term •In-licensed a program (Target Epsilon) that emerged from our fibrosis collab |
|
| February 27, 2024 |
rxrx2023q4website Decoding Biology To Radically Improve Lives February 2024 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation or |
|
| February 13, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Recursion Pharmaceuticals, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 75629V104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245872d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 75629V104 (CUSIP Number) January 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2024 |
Amended and Restated Bylaws of Recursion Pharmaceuticals, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF RECURSION PHARMACEUTICALS, INC. (initially adopted on September 1, 2016) (as amended on January 25, 2024) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF |
|
| January 29, 2024 |
RXRX / Recursion Pharmaceuticals, Inc. / ARK Investment Management LLC - SC 13G Passive Investment SC 13G 1 tm244117d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 75629V104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 8, 2024 |
January 2024 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Co |
|
| December 20, 2023 |
rxrx2023q3decwebsite Decoding Biology To Radically Improve Lives December 2023 2 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| December 20, 2023 |
Exhibit 99.1 Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. Kyiv, Ukraine/Salt Lake City, US: Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industr |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| December 15, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| December 15, 2023 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 . PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to 3,225,902 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 3,225,902 shares of our Class A Common Stock, or the Shares, |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| November 9, 2023 |
Master Agreement between the Company and Tempus Labs, Inc dated November 3, 2023 Exhibit 10.4 CERTAIN INFORMATION, MARKED BY BRACKETS AND ASTERISKS [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Master Agreement This Master Agreement (inclusive of all Exhibits and Order Forms, the “Agreement”) is entered into by and between Tempus Labs, Inc. (on behalf of itself an |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECUR |
|
| November 9, 2023 |
Exhibit 99.2 Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA and Updated Focus of Collaboration with Bayer to Precision Oncology With additional patient centric data, compute power and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio. SALT LAKE CITY, November 9, 2023 — Recursion ( |
|
| November 9, 2023 |
Decoding Biology To Radically Improve Lives End of Q3 2023 2 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| November 9, 2023 |
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results •Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI models together with Recursion's proprietary data and for designing biomarker and patient stratification strategies for clinical programs •Expansion |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) |
|
| October 2, 2023 |
Decoding Biology To Radically Improve Lives Early October 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) ( |
|
| September 5, 2023 |
rxrx2023sepwebsite Decoding Biology To Radically Improve Lives Early September, 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| September 5, 2023 |
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection Exhibit 99.1 Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection ●REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events ●Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024 SALT LAKE CITY, September 5, 2023 - Recursion (NASDAQ: |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of |
|
| August 8, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered Proposed ma |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| August 8, 2023 |
Exhibit 99.2 Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds •Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library •These advances were made possible by NVIDIA DGX Cloud supercomputing a |
|
| August 8, 2023 |
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results •Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world's largest searchable chemical library •Added, accelerated or tightened guidance for clinical study re |
|
| August 8, 2023 |
Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 . PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to 7,706,363 Shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the proposed resale or other disposition from time to time of up to 7,706,363 shares of our Class A Common Stock, or the Shares, |
|
| August 8, 2023 |
rxrxq2finalxwebsite Decoding Biology To Radically Improve Lives End of Q2, 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| August 8, 2023 |
Recursion Pharmaceuticals, Inc. Up to $300,000,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 PROSPECTUS SUPPLEMENT (to Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to $300,000,000 Class A Common Stock We have entered into an Open Market Sale AgreementSM, dated as of August 8, 2023, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our Class A common stock, par value |
|
| August 8, 2023 |
Employment Offer Letter, dated May 19, 2023, between the Registrant and Dr. David Mauro, M.D., Ph.D. 41 S. Rio Grande Street Salt Lake City, Utah 84101 (385) 269-0203 recursionpharma.com May 19, 2023 David Mauro Re: Employment Offer Letter Dear David: Recursion Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) is truly excited to extend you an offer on the terms and conditions in this letter agreement (the “Agreement”) and hope that you will be joining us in our mission of decoding biol |
|
| August 8, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(7) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| August 8, 2023 |
Open Market Sales Agreement dated August 8, 2023 by and between the Registrant and Jefferies LLC Exhibit 10.6 OPEN MARKET SALES AGREEMENT1 August 8, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| July 12, 2023 |
Exhibit 99.1 Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster SALT LAKE CITY, TORONTO & MONTRÉAL (July 12, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio com |
|
| July 12, 2023 |
Registration Rights Agreement, dated July 11, 2023, by and among the Registrant and NVIDIA. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of July 11, 2023 by and among Recursion Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the undersigned purchaser (the “Purchaser”). RECITALS WHEREAS, the Company and the Purchaser are parties to the Stock Purchase Agree |
|
| July 12, 2023 |
Stock Purchase Agreement, dated July 11, 2023, by and among the Registrant and NVIDIA. Exhibit 10.1 STOCK PURCHASE AGREEMENT BY AND BETWEEN RECURSION PHARMACEUTICALS, INC., AND THE PURCHASER AS SET FORTH HEREIN JULY 11, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 6 3.1 Organization and Power 6 3.2 Capitalization 6 3.3 Registration Rights 7 3.4 Authorization 7 3.5 Valid Issuan |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Comm |
|
| June 13, 2023 |
ex991june2023deck Early June 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| June 9, 2023 |
Exhibit 107 Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation Amount to be registered(1) Proposed |
|
| June 9, 2023 |
Exhibit 4.1 REGISTRATION AGREEMENT This REGISTRATION AGREEMENT (this “Agreement”), dated as of May 25, 2023 is by and among Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Acquiror Parent”), Recursion Canada Inc., a corporation governed by the laws of the Province of Ontario (“Acquiror”), Cyclica Therapeutics Inc. (formerly Cyclica Inc.), a corporation governed by the laws of British |
|
| June 9, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264845 . PROSPECTUS SUPPLEMENT (To Prospectus dated May 10, 2022) Recursion Pharmaceuticals, Inc. Up to 5,755,900 Shares of Class A Common Stock Offered by Selling Stockholders Up to 203,124 Shares of Class A Common Stock Issuable Upon Exercise of Certain Outstanding Options We registering the proposed resale or other disposition from time to t |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 30, 2023 |
Exhibit 4.3 REGISTRATION AGREEMENT This REGISTRATION AGREEMENT (this “Agreement”), dated as of May 16, 2023 is by and among Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Acquiror Parent”), 14998685 Canada Inc., a corporation governed by the laws of Canada (“Acquiror”), Valence Discovery Inc., a corporation governed by the laws of Canada (the “Company”), the shareholders of the Comp |
|
| May 30, 2023 |
Cyclica Inc. Second Amended and Restated Stock Option Plan. Exhibit 4.4 CYCLICA INC. SECOND AMENDED AND RESTATED STOCK OPTION PLAN Cyclica Inc. (the “Corporation”) hereby adopts this Second Amended and Restated Stock Option Plan (the “Plan”) for certain Employees, Directors and Consultants of the Corporation and/or its Affiliates. Article 1 Purpose 1.1Purpose. The purpose of the Plan is to attract and retain Employees, Directors or Consultants of the Corpo |
|
| May 30, 2023 |
Exchangeable Share Support Agreement, dated May 8, 2023. Exhibit 4.2 EXCHANGEABLE SHARE SUPPORT AGREEMENT This EXCHANGEABLE SHARE SUPPORT AGREEMENT made as of May 16, 2023 among Recursion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), 1414517 B.C. Unlimited Liability Company, an unlimited liability company existing under the laws of the Province of British Columbia (“Callco”) and 14998685 Canada Inc, a corporation governed by the laws of Cana |
|
| May 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 25, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 22, 2023 |
Exhibit 99.1 Page 1 of 1 CUSIP No. 75629V104 JOINT FILING AGREEMENT Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Statement on Schedule 13G with respect to the Class A Common Stock, par value $0.00001 per share, of Recursion Pharmaceuticals, Inc., to which thi |
|
| May 22, 2023 |
RXRX / Recursion Pharmaceuticals Inc - Class A / Kinnevik AB (publ) - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Recursion Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.00001 per share (Title of Class of Securities) 75629V104 (CUSIP Number) May 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| May 18, 2023 |
Exhibit 4.4 VALENCE DISCOVERY INC. STOCK OPTION PLAN DATED APRIL 17, 2018 AS AMENDED AND RESTATED ON NOVEMBER 16, 2021. 1.Purpose The purpose of this Amended and Restated stock option plan (the “Plan”) is to advance the interests of Valence Discovery Inc. (the “Corporation”) and its shareholders by providing to its directors, officers, employees and consultants a performance incentive for continue |
|
| May 18, 2023 |
As filed with the Securities and Exchange Commission on May 17, 2023 As filed with the Securities and Exchange Commission on May 17, 2023 Registration No. |
|
| May 18, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commi |
|
| May 17, 2023 |
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer Exhibit 99.1 Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer SALT LAKE CITY (May 16, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer. Dr. Mauro will lead Recursion’s pipeline into and through clinical development, |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION |
|
| May 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Recursion Pharmaceuticals, Inc. |
|
| May 8, 2023 |
Exhibit 99.1 Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities SALT LAKE CITY, TORONTO & MONTRÉAL (May 8, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery spac |
|
| May 8, 2023 |
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results Exhibit 99.1 Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results •Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological targets •Advanced 4 active clinical trials, including an exploratory Phase 2 study of REC-994 in Cerebr |
|
| May 8, 2023 |
As filed with the Securities and Exchange Commission on May 8, 2023 As filed with the Securities and Exchange Commission on May 8, 2023 Registration No. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Commis |
|
| May 8, 2023 |
rxrx2023q1website End of Q1 2023 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| April 28, 2023 |
COURTESY PDF OF PROXY STATEMENT 6ATccTaUaDda 8(dSTaPS8:D WSdKZSdWZaVWd( ASXWVifZSeWeWaXYdSffgVWXadkagdUafgWVegbbadfaXJWUgdeaSVagdeeafaWUaVW:aaYkfaJSVUSk AbdahWDhWe*. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (Com |
|
| February 27, 2023 |
Exhibit 99.1 Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results •Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readouts •Delivered against core elements of our Roche-Genentech collaboration (neuroscience and an indication in gastrointestinal oncology) and Bayer collab |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation or |
|
| February 27, 2023 |
2021 Equity Incentive Plan and forms of agreements thereunder Exhibit 10.3 RECURSION PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and •to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock O |
|
| February 27, 2023 |
rxrx2022q4website End of Q4 2022 This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. |
|
| February 27, 2023 |
exhibit108-vestarofficel DocuSign Envelope ID: Dl F7393F-D384-4DF7-M06-1 B9C9421 1 CDA OFFICE LEASE This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between VESTAR GATEWAY, LLC, a Delaware limited liability company (“Landlord”), and RECURSION PHARMACEUTICALS, INC. |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Phar |
|
| February 27, 2023 |
Exhibit 21.1 List of Subsidiaries The following is a list of subsidiaries of Recursion Pharmaceuticals Inc. as of December 31, 2022. Name of Subsidiary* Jurisdiction of Incorporation Recursion Canada Inc. Canada *Inclusion on the list above is not an admission that any of the above entities, individually or in the aggregate, constitutes a significant subsidiary within the meaning of Rule 1-02(w) o |
|
| February 14, 2023 |
RXRX / Recursion Pharmaceuticals, Inc. Class A / Lux Capital Management, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RECURSION PHARMACEUTICALS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 75629V104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| February 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Recursion Pharmaceuticals Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 75629V104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| January 25, 2023 |
Breakfast (8:30 – 9:30 AM) Welcome Tina Larson, President & COO R. Martin Chavez PhD, Chairman State of Recursion Chris Gibson PhD, Co-Founder & CEO Recursion OS Imran Haque PhD, VP of Data Science Lina Nilsson PhD, VP of Product Pre-Clinical Opportunities Laura Schaevitz PhD, SVP and Head of Research Tours & Demos Ben Mabey, Chief Technology Officer Lunch (12:00 – 1:00 PM) Welcome Back Heather Ki |
|
| January 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
|
| January 10, 2023 |
EX-99.1 2 d448685dex991.htm EX-99.1 Exhibit 99.1 DECODING BIOLOGY TO RADICALLY IMPROVE LIVES RECURSION JP Morgan Healthcare Conference January 10th, 2023 DISCLAIMERS This presentation and any accompanying discussion and documents contain information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These forward-looking |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40323 46-4099738 (State or other jurisdiction of incorporation) (C |
